MAPK-IN-2

• UNSPSC Description:

  MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFRWT IC50=281 nM, c-MET IC50=205 nM, B-RAFWT IC50=112 nM, and CDK4/6 IC50=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFRT790M IC50=69 nM and B-RAFV600E IC50=83 nM)[1].

• Target Antigen:

  CDK; c-Met/HGFR; EGFR; p38 MAPK; Raf

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;JAK/STAT Signaling;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/mapk-in-2.html

• Solubility:

  DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1C(C#N)=C(C2=CC=C(Cl)C=C2Cl)C=C(C3=CNC4=C3C=CC=C4)N1

• Molecular Weight:

  380.23

• References & Citations:

  [1]Saleh MM, et al. The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives. Eur J Med Chem. 2023 Nov 5;259:115675.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported